in the absence of a submission from the holder of the marketing authorisation:
trastuzumab deruxtecan (Enhertu®) is not recommended for use within NHSScotland.
Indication under review: as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.
Download detailed advice236KB (PDF)
Medicine details
- Medicine name:
- trastuzumab deruxtecan (Enhertu)
- SMC ID:
- SMC2706
- Indication:
As monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
- Pharmaceutical company
- Daiichi Sankyo UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 12 August 2024